Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets. 

Biotechnology

Assembly Biosciences

Jason Okazaki

Anuj Gaggar

Zhixin Z.

Suzette DeVito

Qi Huang

John O. Gunderson

Grace Wang

Gayan Bogollaga

Nicole S. White

William Delaney

Jennifer Troia

The Leadership Team at Assembly Biosciences is responsible for setting the strategic direction and vision of the company, guiding its clinical and operational initiatives to develop curative therapies for hepatitis B. Comprising key executives with expertise in science, operations, and human resources, this team ensures effective decision-making, fosters innovation in drug development, and oversees the company's growth and performance in the biotechnology sector.

Leadership Team

Directors and Senior Directors Team

Scientific Team

Leadership Team

About

Team members

Other teams at Assembly Biosciences

Directors and Senior Directors Team

Scientific Team